Work

New onset atrial fibrillation after transcatheter aortic valve implantation in Southwestern Colombia between 2009 and 2023

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background New-onset atrial fibrillation (NOAF) is an important complication after transcatheter aortic valve implantation (TAVI). Methods This retrospective cohort included 218 patients without documented pre-existing atrial fibrillation who underwent TAVI in Cali, Colombia, between 2009 and 2023. NOAF required an electrocardiographically documented episode lasting at least 30 s within 30 days. Clinical surveillance included inpatient telemetry and ECGs, scheduled follow-up and institutional readmissions; individual follow-up completeness was not quantified. We compared categorical characteristics and performed a sensitivity analysis restricted to recorded severe or critical aortic stenosis. Results NOAF was documented in 44/218 patients (20.2%; 95% CI, 15.4–26.0%). In the restricted subset, 35/164 had documented NOAF (21.3%; 95% CI, 15.8–28.2%). Chronic obstructive pulmonary disease was more frequent among patients with NOAF (61.4% versus 31.0%; unadjusted OR, 3.53; 95% CI, 1.78–7.01). Pacemaker implantation and low-molecular-weight heparin use were also more frequent in that group, describing perioperative co-occurrence. Conclusion Approximately one-fifth of patients had NOAF documented in the available records. Restriction to recorded severe or critical stenosis produced a similar frequency. The estimate describes clinical documentation within a 30-day window and requires interpretation in light of incomplete ascertainment and indication verification.
Language: English
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7234374041
FWCI:
Cites: 16
Cited by:
Related to: 10
Parts: 2